Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder. Rejoyn (formerly CT-152), a ...

The decision means Germany's GAIA will regain rights to the DTx, called Deprexis, in the US, and comes as the American market for digital health technologies continues to be hampered by an ...

While developments in the industry and technology continue, a new hybrid platform that will redefine trade stands out. DTX Exchange's tokenized model, where global investors aim to access stocks and ...